4'-Methoxy-α-pyrrolidinopropiophenone
![]() |
|
Systematic (IUPAC) name | |
---|---|
(RS)-1-(4-methoxyphenyl)-2-(1-pyrrolidinyl)-1-propanone
|
|
Clinical data | |
Legal status |
|
Routes of administration |
oral, insufflation, vaporization, IV |
Identifiers | |
PubChem | CID: 6430836 |
ChemSpider | 4936174 |
UNII | OI15TPX8QP ![]() |
Chemical data | |
Formula | C14H19NO2 |
Molecular mass | 233.305 g/mol |
|
|
|
|
4'-Methoxy-α-pyrrolidinopropiophenone (MOPPP) is a stimulant drug, chemically similar to amphetamine ("speed") and MDMA ("ecstasy"). It is a designer drug and has the potential to produce a drug high.
Recreational usage
<templatestyles src="Module:Hatnote/styles.css"></templatestyles>
MOPPP use is infrequent when compared to other amphetamines or stimulants used recreationally, such as meth, cocaine, or speed. It first arose as a designer drug in Germany in the late 1990s and early 2000s,[1][2][3] along with a number of other derivatives but never gained the international popularity[4][5] that other drugs in its family of pyrrolidinophenone derivatives had (such as α-PPP and MDPV).
While the recent trend of selling stimulants through false labeling (i.e., bath salts) has gained notoriety, using MDPV as its main ingredient, this has not been the case with MOPPP, despite its similar potential for abuse.[6]
Chemistry
MOPPP is structurally related to α-PPP in the same way that PMA is related to amphetamine: a methoxy group has been added to the 4-position on the phenyl ring.
Metabolism
MOPPP appears to be metabolized within the liver chiefly by the enzyme CYP2D6.[2]
See also
- α-Pyrrolidinopropiophenone (α-PPP)
- 4'-Methyl-α-pyrrolidinopropiophenone (MPPP)
- 3,4-Methylenedioxy-α-pyrrolidinopropiophenone (MDPPP)
- 3',4'-Methylenedioxy-α-pyrrolidinobutiophenone (MDPBP)
- Methyldioxymethamphetamine (MDMA) or Ecstasy
- Trifluoromethylphenylpiperazine (TMPPP) or "Molly"[7]
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references>
tag; parameter "group" is allowed only.
<references />
, or <references group="..." />
|
|||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ 2.0 2.1 Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- Pages with reference errors
- Use dmy dates from December 2013
- Chemical articles having calculated molecular weight overwritten
- Chemical articles with unknown parameter in Infobox drug
- Infobox drug articles without a structure image
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugboxes with an unspecified ATC code
- Articles containing unverified chemical infoboxes
- Designer drugs
- Stimulants
- Pyrrolidinophenones
- Phenol ethers